Autologous Serum from Sjögren’s Syndrome Patients Mitigates Ferroptosis in Hyperosmolarity-Induced Corneal Epitheliopathy
Journal of Ocular Pharmacology and Therapeutics · 01.09.2025 · 41 (7) · 397-407
DOI: 10.1089/jop.2025.0025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, online erschienen am 11.06.2025. Verfasst von Guanghong Chu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing Key Laboratory of Ophthalmology, Chongqi…. Hauptthemen laut MEDLINE: Ferroptosis, Sjogren's Syndrome, Serum, Epithelium, Corneal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Purpose
To investigate the role of autologous serum (AS) in alleviating hyperosmolarity-induced corneal epitheliopathy via the ferroptosis pathway.
Methods
AS was extracted and prepared from patients with Sjögren’s syndrome. An in vitro hyperosmotic dry eye model was established by exposing HCE-T cells to 90 mM NaCl, followed by treatment with AS or ferroptosis inhibitors. Protein expression was analyzed using Western blotting. Intracellular Fe 2+ and reactive oxygen species (ROS) levels were determined by FerroOrange and 2’,7’-Dichlorodihydrofluorescein diacetate (H2DCFDA) fluorescent probes, and cellular malondialdehyde and glutathione levels were measured using kits. Transmission electron microscopy was utilized to examine mitochondrial ultrastructure.
Results
Under hyperosmotic conditions, HCE-T cells exhibited increased lipid peroxidation and iron accumulation, accompanied by significant alterations in the expression of ferroptosis-related markers and characteristic changes in mitochondrial morphology, which indicated the induction of ferroptosis. Among the tested concentrations, 20% and 50% AS demonstrated notable therapeutic effects, significantly enhancing cell viability and migration, reducing ROS and Fe 2+ levels, and alleviating mitochondrial damage. Furthermore, AS effectively inhibited ferroptosis through the Xc − /glutathione peroxidase 4 (GPX4) pathway.
Conclusions
AS reduced lipid peroxidation levels in HCE-T cells under hyperosmolarity and inhibited ferroptosis through the Xc − /GPX4 pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, The First Affiliated Hospital of Chongqing Medical U…
- Department of Combination of Chinese and Western Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, P. R. China.
Zitieren
APA
Chu, G., Wang, J., Wang, Z., Cai, X., Shi, S., Qing, Q., Zhong, Y., & Zhang, Q. (2025). Autologous Serum from Sjögren’s Syndrome Patients Mitigates Ferroptosis in Hyperosmolarity-Induced Corneal Epitheliopathy. Journal of Ocular Pharmacology and Therapeutics, 41(7), 397-407. https://doi.org/10.1089/jop.2025.0025
Vancouver
Chu G, Wang J, Wang Z, Cai X, Shi S, Qing Q, et al. Autologous Serum from Sjögren’s Syndrome Patients Mitigates Ferroptosis in Hyperosmolarity-Induced Corneal Epitheliopathy. Journal of Ocular Pharmacology and Therapeutics. 2025;41(7):397-407. doi:10.1089/jop.2025.0025
BibTeX
@article{Chu2025,
author = {Chu, Guanghong and Wang, Jiao and Wang, Zihuan and Cai, Xiaoyu and Shi, Siyuan and Qing, Qiping and Zhong, Yu and Zhang, Qi},
title = {Autologous Serum from Sjögren’s Syndrome Patients Mitigates Ferroptosis in Hyperosmolarity-Induced Corneal Epitheliopathy},
journal = {Journal of Ocular Pharmacology and Therapeutics},
year = {2025},
volume = {41},
number = {7},
pages = {397--407},
doi = {10.1089/jop.2025.0025}
}
EUVIMED